Strategies for improving the management of immune-related adverse events by James L Gulley, Patrick Hwu, Gennaro Ciliberto, Aung Naing, Funda Meric-Bernstam, Michael B Atkins, Joud Hajjar

Get full text

PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma by Michael B. Atkins, Suthee Rapisuwon, Arash Radfar, Kellie Gardner, Neil J. Shah, Geoffrey T. Gibney, Jacob Zaemes, Shelly Shand, David Swoboda, Vesna Petronic-Rosic, Michael J. Reilly, Waddah B. Al-Refaie

Get full text

Role of high-dose interleukin-2 for melanoma in the age of cellular therapy by Mario Sznol, Elizabeth Buchbinder, Rodabe Amaria, Amod Sarnaik, David F McDermott, Michael B Atkins, Ann W Silk, Kim A Margolin, Michael T Lotze, Zeynep Eroglu, Virginia Seery, Allison Betof Warner, Harriet M Kluger, Karam Khaddour

Get full text

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A) by Michael Hurwitz, Mark Stein, Jeffrey Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Meredith M Regan, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Paul J Catalano

Get full text